SCHEMBL114672

SCHEMBL114672

[CH]1CCCONC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL420627 0.92
SCHEMBL20488959 0.82
SCHEMBL19183385 0.76
SCHEMBL1827921 0.65
SCHEMBL19893779 0.63
SCHEMBL20816989 0.59
SCHEMBL7781364 0.59
SCHEMBL6570160 0.59 TSHR (0.36)
SCHEMBL916800 0.59
SCHEMBL1560426 0.57

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 851 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023107490-A1 HETEROCYCLE-CONTAINING LONP1 INHIBITOR COMPOUNDS, USES AND METHODS PRETZEL THERAPEUTICS, INC. (US) 2023-06-15 WO claimed
WO-2023091229-A1 SMALL MOLECULE BINDERS OF THE ONCOGENIC FUSION TRANSCRIPTION FACTOR PAX3-FOXO1 MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2023-05-25 WO claimed
EP-3924340-A1 INDAZOLYL-ISOXAZOLE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER Merck Patent GmbH (DE) 2021-12-22 EP claimed
EP-3890716-A1 COMBINATION THERAPIES Mirati Therapeutics, Inc. (US) 2021-10-13 EP claimed
EP-3849534-A1 COMBINATION THERAPIES Mirati Therapeutics, Inc. (US) 2021-07-21 EP claimed
EP-3849535-A1 COMBINATION THERAPIES Mirati Therapeutics, Inc. (US) 2021-07-21 EP claimed
EP-3849537-A1 COMBINATION THERAPIES Mirati Therapeutics, Inc. (US) 2021-07-21 EP claimed
EP-3849538-A1 COMBINATION THERAPIES Mirati Therapeutics, Inc. (US) 2021-07-21 EP claimed
EP-3849536-A1 COMBINATION THERAPIES Mirati Therapeutics, Inc. (US) 2021-07-21 EP claimed
EP-3843741-A1 IRE1 KINASE INHIBITORS AND USES THEREOF The Regents of the University of California (US) 2021-07-07 EP claimed
WO-2004101554-A1 NEW INDOLE DERIVATIVES AS FACTOR XA INHIBITORS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2004-11-25 WO claimed
WO-2004101556-A1 INDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2004-11-25 WO claimed
EP-1479678-A1 Pyrazole-derivatives as factor xa inhibitors Aventis Pharma Deutschland GmbH (DE) 2004-11-24 EP claimed
WO-2004056815-A1 PYRAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-07-08 WO claimed
WO-2004050636-A2 IMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-06-17 WO claimed
US-20040053957-A1 Substituted 3-amino-thieno [2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2004-03-18 US claimed
WO-2003103661-A1 SUBSTITUTED 3-AMINO-THIENO[2,3-b]PYRIDINE-2-CARBOXYLIC ACID AMIDE COMPOUNDS AND PROCESSES FOR PREPARING AND THEIR USES BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2003-12-18 WO claimed
WO-2002100849-A2 NOVEL NITRILES USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2002-12-19 WO claimed
US-5025005-A Preventive or therapeutic agents for circulatory diseases, allergic disorders; antineoplastic agent; inhibitor for platelet activating factor TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1991-06-18 US claimed
US-4737518-A ANTIALLERGENS, ANTINEOPLASTICS, ANTICOAGULANTS, CIRCULATORY DISEASES TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1988-04-12 US claimed